SCHEMBL272144

SCHEMBL272144

COC[C@@H]1CNCCO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL271860 1.00 — —
SCHEMBL271861 1.00 — —
Hydrochloric Acid SCHEMBL272352 0.98 ADRA2C (0.54) —
Hydrochloric Acid SCHEMBL272353 0.98 ADRA2C (0.54) —
Hydrochloric Acid SCHEMBL3942366 0.98 ADRA2C (0.54) —
SCHEMBL30736306 0.88 ADRA2C (0.45) —
SCHEMBL31642501 0.86 — —
Hydrochloric Acid SCHEMBL31642735 0.85 SLC6A4 (0.47) —
SCHEMBL23581722 0.82 ADRA2C (0.40) —
SCHEMBL23581729 0.82 ADRA2C (0.40) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4029868-B1 MCL-1 INHIBITORS GILEAD SCIENCES INC (US) 2026-05-20 — — EP disclosed
CN-117304130-A MCL-1 inhibitors 吉利德科学公司 2023-12-29 — — CN disclosed
WO-2023230609-A1 HETEROCYCLIC PAD4 INHIBITORS CELGENE CORPORATION (US) 2023-11-30 — — WO disclosed
US-20230312490-A1 MCL-1 INHIBITORS GILEAD SCIENCES, INC. 2023-10-05 — — US disclosed
CN-112118845-B MCL-1 inhibitors 吉利德科学公司 2023-06-13 — — CN disclosed
US-11643400-B2 MCL-1 inhibitors GILEAD SCIENCES, INC. (US) 2023-05-09 — — US disclosed
US-20220340535-A1 MCL-1 INHIBITORS GILEAD SCIENCES, INC. 2022-10-27 — — US disclosed
EP-4029868-A1 MCL-1 INHIBITORS GILEAD SCIENCES, INC. (US) 2022-07-20 — — EP disclosed
EP-3992197-A1 NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUNDS, AND PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Applied Pharmaceutical Science, Inc. (CN) 2022-05-04 — — EP disclosed
US-20220017539-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUND, COMPOSITION CONTAINING THE SAME AND USE THEREOF SHENZHEN TARGETRX, INC. (CN) 2022-01-20 — — US disclosed
US-20090280083-A1 Compounds for the Treatment of Hepatitis C BRISTOL-MYERS SQUIBB COMPANY 2009-11-12 — — US disclosed
US-20090280083-A1 Compounds for the Treatment of Hepatitis C BRISTOL-MYERS SQUIBB COMPANY 2009-11-12 — — US disclosed
WO-2009137454-A1 7H-INDOLO[2,1-A] [2] BENZAZEPINE-10-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF HEPATITIS C BRISTOL-MYERS SQUIBB COMPANY (US) 2009-11-12 — — WO disclosed
US-20090275561-A1 Compounds for the Treatment of Hepatitis C BRISTOL-MYERS SQUIBB COMPANY 2009-11-05 — — US disclosed
US-20090074715-A1 Compounds for the Treatment of Hepatitis C BRISTOL-MYERS SQUIBB COMPANY 2009-03-19 — — US disclosed
WO-2009029384-A2 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL-MYERS SQUIBB COMPANY (US) 2009-03-05 — — WO disclosed
US-5191079-A Chemical intermediates for bactericides KANEBO, LTD. (JP) 1993-03-02 — — US disclosed
US-5166203-A QUINOLINECARBOXYLIC ACID DERIVATIVES, ANTIBACTERIAL AGENT CONTAINING THE SAME KANEBO, LTD. (JP) 1992-11-24 — — US disclosed
CN-1059339-A New quinoline carboxylic acid derivative, the antiseptic-germicide that contains them and their method for making KANEBO LTD (JP) 1992-03-11 — — CN disclosed
EP-0472826-A2 Novel quinolinecarboxylic acid derivatives, use thereof, antibacterial agent containing the same, process for preparing said compounds and intermediate compound KANEBO LTD. (JP) 1992-03-04 — — EP disclosed
Send feedback